博济医药
(300404)
| 流通市值：41.40亿 | | | 总市值：55.93亿 |
| 流通股本：2.86亿 | | | 总股本：3.86亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 454,140,244.6 | 220,156,809.56 | 868,644,086.02 | 584,317,656.85 |
| 营业收入 | 454,140,244.6 | 220,156,809.56 | 868,644,086.02 | 584,317,656.85 |
| 二、营业总成本 | 420,072,140.2 | 196,959,149.06 | 822,637,193.21 | 554,800,483.18 |
| 营业成本 | 336,768,308.33 | 157,520,877.07 | 633,027,989.14 | 415,847,176.08 |
| 税金及附加 | 3,406,807.78 | 1,581,829.48 | 7,569,155.46 | 5,374,166.84 |
| 销售费用 | 25,493,073.83 | 11,910,238.41 | 56,883,114.31 | 41,415,253.66 |
| 管理费用 | 30,635,082.34 | 13,828,815.66 | 66,675,417.4 | 52,257,776.08 |
| 研发费用 | 23,520,008.03 | 11,901,099.26 | 57,497,869.16 | 38,925,834.02 |
| 财务费用 | 248,859.89 | 216,289.18 | 983,647.74 | 980,276.5 |
| 其中:利息费用 | 637,331.84 | 310,285.3 | 1,675,585.04 | 1,249,884.25 |
| 其中:利息收入 | 300,190.12 | 79,933.52 | 830,750.02 | 413,797.57 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,742,517.15 | 839,242.57 | 1,482,850.18 | 1,312,070.54 |
| 加:投资收益 | 11,981,021.59 | 443,192.39 | 837,663.49 | 422,611.89 |
| 资产减值损失(新) | -252,902.12 | -162,731.61 | -10,211,557.18 | -6,434,398.97 |
| 信用减值损失(新) | -10,079,713.2 | -5,905,506.67 | -19,896,365.19 | -13,636,718.7 |
| 其他收益 | 2,863,919.48 | 1,273,070.46 | 13,063,692.05 | 7,428,366.12 |
| 四、营业利润 | 40,322,947.3 | 19,684,927.64 | 31,283,176.16 | 18,609,104.55 |
| 加:营业外收入 | 136.58 | 2,527.52 | 11,722.18 | 2,224.58 |
| 减:营业外支出 | 58,636.44 | 7,215.44 | 1,238,227.78 | 280,696.32 |
| 五、利润总额 | 40,264,447.44 | 19,680,239.72 | 30,056,670.56 | 18,330,632.81 |
| 减:所得税费用 | 2,516,157.12 | 3,610,024.19 | -2,853,123.8 | -5,536,883.38 |
| 六、净利润 | 37,748,290.32 | 16,070,215.53 | 32,909,794.36 | 23,867,516.19 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 37,748,290.32 | 16,070,215.53 | 32,909,794.36 | 23,867,516.19 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 37,200,513.01 | 16,460,786.19 | 30,494,240.6 | 21,913,904.3 |
| 少数股东损益 | 547,777.31 | -390,570.66 | 2,415,553.76 | 1,953,611.89 |
| 扣除非经常损益后的净利润 | 22,391,063.08 | 13,708,421.47 | 19,204,404.82 | 14,981,173.93 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.04 | 0.08 | 0.06 |
| (二)稀释每股收益 | 0.1 | 0.04 | 0.08 | 0.06 |
| 八、其他综合收益 | -1,391,854.46 | -242,885.29 | -1,199,416.73 | -395,881.93 |
| 归属于母公司股东的其他综合收益 | -1,381,938.55 | -238,236.34 | -1,192,448.68 | -391,976.91 |
| 九、综合收益总额 | 36,356,435.86 | 15,827,330.24 | 31,710,377.63 | 23,471,634.26 |
| 归属于母公司股东的综合收益总额 | 35,818,574.46 | 16,222,549.85 | 29,301,791.92 | 21,521,927.39 |
| 归属于少数股东的综合收益总额 | 537,861.4 | -395,219.61 | 2,408,585.71 | 1,949,706.87 |
| 公告日期 | 2026-08-27 | 2026-04-25 | 2026-04-25 | 2025-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |